Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)

India flag India · Delayed Price · Currency is INR
503.60
-12.80 (-2.48%)
Mar 7, 2025, 9:15 AM IST
-30.54%
Market Cap 79.96B
Revenue (ttm) 40.10B
Net Income (ttm) 1.49B
Shares Out 157.39M
EPS (ttm) 10.14
PE Ratio 50.12
Forward PE 28.54
Dividend n/a
Ex-Dividend Date n/a
Volume 142,747
Average Volume 380,476
Open 513.55
Previous Close 516.40
Day's Range 500.00 - 518.90
52-Week Range 432.60 - 1,175.90
Beta n/a
RSI 48.42
Earnings Date Jun 17, 2025

About NSE:AKUMS

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. It offers dosage forms, such as tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form fill seals, topical preparations, eye drops, dry powder injections, rotacaps and gummies, and others. The company operates as pharmaceutical contract development and manufacturing company. It also sells branded pharmaceutical formulations. The company was incorporated in 2004 and... [Read more]

Sector Healthcare
Founded 2004
Employees 7,388
Stock Exchange National Stock Exchange of India
Ticker Symbol AKUMS
Full Company Profile

Financial Performance

Financial Statements

News

Akums Drugs and Pharmaceuticals shares fall over 6% following Income Tax Department search

Shares of Akums Drugs and Pharmaceuticals fell over 6% on January 22 following the company’s disclosure of an Income Tax Department search at its offices and manufacturing units. In an exchange filing...

7 weeks ago - Business Upturn

Akums Drugs secures Rs 1,760 deal to supply oral liquid formulations in Europe

Akums Drugs and Pharmaceuticals Limited has secured a strategic agreement with a leading global pharmaceutical company for the manufacture and supply of oral liquid formulations in the European market...

2 months ago - Business Upturn

Akums Drugs partners with Jagdale to revolutionize India’s Ready-to-Drink nutritional beverage market

Akums Drugs and Pharmaceuticals Ltd. has announced a strategic collaboration through its subsidiary, Maxcure Nutravedics Ltd., with Jagdale Industries Private Limited to market Ready-to-Drink (RTD) be...

3 months ago - Business Upturn

Akums Drugs shares surge 5% after signing Master Sales Agreement with Caregen

Akums Drugs and Pharmaceuticals saw a 5% jump in its stock price after signing an exclusive Master Sales Agreement with South Korea-based Caregen Co., Ltd. The deal gives Akums exclusive rights to pac...

4 months ago - Business Upturn

Akums Drugs signs Master Sales Agreement with Caregen for Indian Nutraceutical market expansion

Akums Drugs and Pharmaceuticals Ltd., a leading name in the pharmaceutical industry, has signed an exclusive Master Sales Agreement with South Korea’s Caregen Co., Ltd. This partnership grants Akums e...

4 months ago - Business Upturn

Akums Drugs and Pharmaceuticals shares fall 5% following weak Q2 earnings outlook

Shares of Akums Drugs and Pharmaceuticals dropped 5% as the company reported weak Q2 earnings and projected a flat revenue outlook for the fiscal year 2024-25. The stock was trading at ₹582.10 as of 9...

4 months ago - Business Upturn

Akums Drugs and Pharmaceuticals Q2 FY25 results: Revenue at ₹1,033.09 crore, down 12.5% YoY; profit at ₹66.65 crore, up 103.8% YoY

Akums Drugs and Pharmaceuticals Limited has released its financial results for Q2 FY25, showing mixed performance metrics. Key Financial Highlights: Revenue from Operations: For the quarter ended Sept...

4 months ago - Business Upturn

Akums Drugs signs MoU with Zambian Ministry of Health to manufacture local medicine

Akums Drugs and Pharmaceuticals Limited (Akums) has signed a Memorandum of Understanding (MoU) with the Zambian Ministry of Health to manufacture local medicine. The MoU seeks to improve existing coll...

5 months ago - Business Upturn

Akums Drugs shares surge 4% after company bags exclusive rights to develop Triple Hair products in India

Akums Drugs and Pharmaceuticals shares jumped more than 4% after the company announced that it received exclusive rights to develop and market Triple Hair Inc.’s innovative products in India. The deal...

5 months ago - Business Upturn

Akums Drugs secures exclusive rights to develop and market Triple Hair products in India

Akums Drugs and Pharmaceuticals has recently informed exchanges that the company has secured exclusive rights to develop and market Triple Hair Inc.’s innovative products in India. This partnership ma...

5 months ago - Business Upturn

McCormick Q3 Earnings Top Estimates, MKC Volumes Improve Y/Y

McCormick & Company, Incorporated (NYSE: MKC) reported solid third-quarter fiscal 2024 results, wherein the top and bottom lines beat the Zacks Consensus Estimate, and earnings increased year over ye...

5 months ago - Benzinga